A routine arthritis shot for dogs and horses turned into a nationwide recall after glass fibers showed up in retained samples.
Quick Take
- American Regent, Inc. Animal Health recalled two lots of Adequan Canine and two lots of Adequan i.m. nationwide.
- The company said the recall followed testing that found visible glass fiber material in internally retained samples.
- The products were sold to veterinarians, wholesalers, distributors, and online pharmacies across the United States.
- No adverse events had been reported at the time of the recall notice.
What the Recall Covers
The recall focuses on four exact lots: 25011 and 3369 for Adequan Canine, and 24416 and 25265P for Adequan i.m. Adequan Canine is the dog version, while Adequan i.m. is used in horses.
‘Glass Fibers’ Found Inside Dog and Horse Medications Prompt Urgent Nationwide Recall https://t.co/DwIWQV0OxB
— People Pets (@PEOPLEPets) August 7, 2026
The Food and Drug Administration said the products were recalled because glass fibers were found during testing of internally retained samples. That matters because injectable products with particulate matter can cause local irritation, swelling, inflammation, injection site pain, infection, or abscesses.
Why the Company Moved Fast
This kind of recall is built around prevention, not damage control. The company did not wait for a string of injuries to make the call. It pulled specific lots once the contaminant showed up in testing, which is standard when a sterile injectable may carry a foreign-particle risk.
The recall also stayed narrow. It did not cover every Adequan product on the market. It targeted only the listed lots, which suggests the company believed the problem could be isolated to defined batches.
What Pet Owners and Clinics Were Told
The guidance was simple: stop using the affected lots immediately. Clinics, distributors, retailers, and hospitals were told to stop distributing the products and return or discard remaining inventory.
Pet owners were told to contact a veterinarian if an animal had any problems that might be linked to the recalled products. That is the right next step because injection-site reactions can be hard to sort out without a clinical exam.
The distribution trail also shows how far the product had spread before the recall hit. The dog lots were shipped in 2024 and 2025, while the horse lots were shipped in 2025 and early 2026. That long runway makes inventory checks important, because old stock can sit unnoticed on shelves until a recall like this forces a search.
The Bigger Lesson
Foreign material recalls rarely feel dramatic until you think about what is inside the vial. A tiny visible fiber can change how a trusted injectable is viewed overnight.
For veterinarians, the issue is not just product quality. It is the risk of putting a contaminant directly into muscle tissue, where the body may react fast and badly.
That is why these recalls can sound alarming even when no injuries have been reported. The point is to get the product out before a preventable harm turns into a clinic visit, an abscess, or a long complaint trail.
